Refining the DC-targeting Vaccination for Preventing Emerging Infectious Diseases

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Aug 26

PMID 36016929

Authors

Yadira Pastor

Nour Ghazzaui

Adele Hammoudi

Mireille Centlivre

Sylvain Cardinaud

Yves Levy

Affiliations

Soon will be listed here.

Abstract

The development of safe, long-term, effective vaccines is still a challenge for many infectious diseases. Thus, the search of new vaccine strategies and production platforms that allow rapidly and effectively responding against emerging or reemerging pathogens has become a priority in the last years. Targeting the antigens directly to dendritic cells (DCs) has emerged as a new approach to enhance the immune response after vaccination. This strategy is based on the fusion of the antigens of choice to monoclonal antibodies directed against specific DC surface receptors such as CD40. Since time is essential, approaches are of high interest to select the most immunogenic and conserved epitopes to improve the T- and B-cells responses. The purpose of this review is to present the advances in DC vaccination, with special focus on DC targeting vaccines and epitope mapping strategies and provide a new framework for improving vaccine responses against infectious diseases.

Citing Articles

Developing T Cell Epitope-Based Vaccines Against Infection: Challenging but Worthwhile.

Tang X, Zhang W, Zhang Z Vaccines (Basel). 2025; 13(2).

PMID: 40006681 PMC: 11861332. DOI: 10.3390/vaccines13020135.

Adjuvant-free, self-assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses.

Zhao Y, Guo S, Liu J, Wang Y, Wang B, Peng C Front Immunol. 2025; 16:1519866.

PMID: 39958330 PMC: 11827429. DOI: 10.3389/fimmu.2025.1519866.

Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine.

Zhao Y, Liu J, Peng C, Guo S, Wang B, Chen L J Nanobiotechnology. 2025; 23(1):77.

PMID: 39905416 PMC: 11792681. DOI: 10.1186/s12951-025-03122-6.

T-Cell Epitope-Based Vaccines: A Promising Strategy for Prevention of Infectious Diseases.

Song X, Li Y, Wu H, Qiu H, Sun Y Vaccines (Basel). 2024; 12(10).

PMID: 39460347 PMC: 11511246. DOI: 10.3390/vaccines12101181.

An Immunoreceptor-Targeting Strategy with Minimalistic C3b Peptide Fusion Enhances SARS-CoV-2 RBD mRNA Vaccine Immunogenicity.

Chiu C, Tsai H, Chen J, Hu C, Chen H Int J Nanomedicine. 2024; 19:7201-7214.

PMID: 39050877 PMC: 11268571. DOI: 10.2147/IJN.S463546.

References

Patente T, Pinho M, Oliveira A, Evangelista G, Bergami-Santos P, Barbuto J . Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy. Front Immunol. 2019; 9:3176. PMC: 6348254. DOI: 10.3389/fimmu.2018.03176. View

Kastenmuller W, Kastenmuller K, Kurts C, Seder R . Dendritic cell-targeted vaccines--hope or hype?. Nat Rev Immunol. 2014; 14(10):705-11. DOI: 10.1038/nri3727. View

Salabert N, Todorova B, Martinon F, Boisgard R, Zurawski G, Zurawski S . Intradermal injection of an anti-Langerin-HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo. Eur J Immunol. 2015; 46(3):689-700. DOI: 10.1002/eji.201545465. View

Graham J, Authie P, Yu C, Zurawski S, Li X, Marches F . Targeting dendritic cells in humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes. Vaccine. 2016; 34(41):4857-4865. PMC: 5598757. DOI: 10.1016/j.vaccine.2016.08.071. View

Vallon-Eberhard A, Landsman L, Yogev N, Verrier B, Jung S . Transepithelial pathogen uptake into the small intestinal lamina propria. J Immunol. 2006; 176(4):2465-9. DOI: 10.4049/jimmunol.176.4.2465. View

Matos I, Mizenina O, Lubkin A, Steinman R, Idoyaga J . Targeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective Immunity. PLoS One. 2013; 8(6):e67453. PMC: 3694010. DOI: 10.1371/journal.pone.0067453. View

Alix A . Predictive estimation of protein linear epitopes by using the program PEOPLE. Vaccine. 1999; 18(3-4):311-4. DOI: 10.1016/s0264-410x(99)00329-1. View

Segura E . Cross-Presentation Assay for Human Dendritic Cells. Methods Mol Biol. 2016; 1423:189-98. DOI: 10.1007/978-1-4939-3606-9_14. View

Chatterjee B, Smed-Sorensen A, Cohn L, Chalouni C, Vandlen R, Lee B . Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood. 2012; 120(10):2011-20. DOI: 10.1182/blood-2012-01-402370. View

10.

Yin W, Duluc D, Joo H, Xue Y, Gu C, Wang Z . Therapeutic HPV Cancer Vaccine Targeted to CD40 Elicits Effective CD8+ T-cell Immunity. Cancer Immunol Res. 2016; 4(10):823-834. DOI: 10.1158/2326-6066.CIR-16-0128. View

11.

Vremec D, OKeeffe M, Wilson A, Ferrero I, Koch U, Radtke F . Factors determining the spontaneous activation of splenic dendritic cells in culture. Innate Immun. 2010; 17(3):338-52. DOI: 10.1177/1753425910371396. View

12.

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View

13.

Marlin R, Godot V, Cardinaud S, Galhaut M, Coleon S, Zurawski S . Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. Nat Commun. 2021; 12(1):5215. PMC: 8410935. DOI: 10.1038/s41467-021-25382-0. View

14.

Laouar Y, Sutterwala F, Gorelik L, Flavell R . Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol. 2005; 6(6):600-7. DOI: 10.1038/ni1197. View

15.

Kotraiah V, Phares T, Terry F, Hindocha P, Silk S, Nielsen C . Identification and Immune Assessment of T Cell Epitopes in Five Blood Stage Antigens to Facilitate Vaccine Candidate Selection and Optimization. Front Immunol. 2021; 12:690348. PMC: 8294059. DOI: 10.3389/fimmu.2021.690348. View

16.

Reddy S, Swartz M, Hubbell J . Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 2006; 27(12):573-9. DOI: 10.1016/j.it.2006.10.005. View

17.

Larsen J, Lund O, Nielsen M . Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2:2. PMC: 1479323. DOI: 10.1186/1745-7580-2-2. View

18.

Nielsen M, Lundegaard C, Lund O, Kesmir C . The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics. 2005; 57(1-2):33-41. DOI: 10.1007/s00251-005-0781-7. View

19.

Filley A, Dey M . Dendritic cell based vaccination strategy: an evolving paradigm. J Neurooncol. 2017; 133(2):223-235. PMC: 5532060. DOI: 10.1007/s11060-017-2446-4. View

20.

Leplina O, Starostina N, Zheltova O, Ostanin A, Shevela E, Chernykh E . Dendritic cell-based vaccines in treating recurrent herpes labialis: Results of pilot clinical study. Hum Vaccin Immunother. 2016; 12(12):3029-3035. PMC: 5215391. DOI: 10.1080/21645515.2016.1214348. View